Form 4: Apellis Pharmaceuticals Chief Scientific Officer Sells Shares to Cover Tax Withholding
SEC Form 4 Filing
Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, sold 2,288 shares of common stock on January 13, 2025, to cover tax obligations related to released Restricted Stock Units.
Summary
- On January 13, 2025, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, sold 2,288 shares of the company's common stock.
- The sale was executed at a price of $28.7021 per share.
- This transaction was conducted to cover tax withholding obligations associated with Restricted Stock Units that were released on January 10, 2025.
- Following the transaction, Deschatelets directly owns 1,138,195 shares of Apellis Pharmaceuticals.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine Form 4 filing, reflecting an insider's stock sale to cover tax obligations, which is a common practice.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Restricted Stock Units released. |
| 01/13/2025 | Date of stock sale transaction. |
| 01/14/2025 | Date of signature by attorney-in-fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.